New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
11:46 EDTNVS, TEVACourt says Barr Labs did not infringe on Alcon patents, Reuters says
U.S. appeals court upholds finding that Barr Laboratories (TEVA) did not infringe two Alcon (NVS) research patents that relate to glaucoma and ocular hypertension drug Travatan, but reverses finding that Alcon's claims were invalid, says Reuters. Reference Link
News For NVS;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 27, 2015
10:41 EDTTEVATeva reiterates commitment to acquisition for Mylan for $82 per share
Teva (TEVA) reiterated its commitment to its proposed combination with Mylan (MYL). As previously announced on April 21, 2015, Teva has proposed to acquire Mylan for $82.00 per share, with the consideration to be comprised of approximately 50% cash and 50% stock. Teva’s proposal for Mylan implies a total equity value of approximately $43B. Teva noted that the board and management team are committed to consummating a transaction as soon as possible. It continues to believe that the Teva proposal is "extremely attractive" for Myland stockholders, that owuld deliver more value than any other alternative. As previously announced, the transaction would not be subject to a financing condition or require a Teva stockholder vote. Teva’s proposal is contingent on Mylan not completing its proposed acquisition of Perrigo or any alternative transactions.
10:30 EDTNVSNovartis says Phase III Arzerra study met primary endpoint
Subscribe for More Information
09:48 EDTTEVACNBC discusses Mylan patent challenges on Copaxone
Subscribe for More Information
09:22 EDTTEVAMylan board unanimously rejects expression of interest from Teva
Subscribe for More Information
09:20 EDTTEVAMylan board unanimously rejects expression of interest from Teva
07:15 EDTTEVAMylan Perrigo offer makes Teva acquisition more likely, says Wells Fargo
After Mylan (MYL) announced its formal takeover offer for Perrigo (PRGO), Wells Fargo says that Mylan's lower than expected synergy guidance and the confirmation that Mylan shareholders will be required to approve the deal increase the chances that Teva will wind up buying Mylan. Wells continues to believe that Teva can significantly increase its bid for Mylan and that Mylan may have difficulty rejecting such an offer.
06:34 EDTTEVAOncoGenex subsidiary executes termination agreement with Teva
Subscribe for More Information
06:34 EDTTEVACiti says Teva, Mylan deal 'more likely than not'
Citigroup views a Teva (TEVA), Mylan (MYL) combination as "more likely than not" after Perrigo (PRGO) rejected Mylan's (MYL) second proposal to acquire the company. Citi believes investors are likely under appreciating how quickly a potential deal can be reached. It anticipates that the stichting set up by the Mylan board could trigger the call option to issue preference shares. Teva could appeal to the Dutch Enterprise Chamber, which Citi believes would likely constitute a "relatively speedy process." It has a Buy rating on Teva with a $70 price target.
06:33 EDTTEVAOncoGenex regains rights to custirsen executes termination agreement with Teva
Subscribe for More Information
06:19 EDTNVSPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
16:31 EDTTEVAStocks finish week higher following strong tech earnings
Subscribe for More Information
12:02 EDTTEVAPerrigo plans to reject Mylan new offer, Bloomberg reports
Subscribe for More Information
07:24 EDTTEVAMylan price target raised to $82 from $65 at Deutsche Bank
Subscribe for More Information
April 23, 2015
14:03 EDTTEVAActive Biotech AB, Teva enroll first patient in Phase 2 study of Laquinimod
Subscribe for More Information
12:32 EDTTEVATeva working with FTC on path toward Mylan deal approval, CT Financial News says
Subscribe for More Information
09:52 EDTNVSEli Lilly sees at least $200M in savings from Novartis Animal Health acquisition
09:01 EDTTEVATeva presents data comparing early treatment with Copaxone to delayed start
Subscribe for More Information
07:16 EDTTEVAMylan the safest bet in generic drug company takeover battle, says Bernstein
Subscribe for More Information
05:25 EDTNVSNovartis backs FY15 revenue guidance of growth in mid-single digits
Subscribe for More Information
05:22 EDTNVSNovartis reports Q1 Core EPS $1.33, consensus $1.10
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use